TNFRSF8 and Hodgkins lymphoma: In the specific case of Hodgkin lymphoma (HL), monoclonal antibodies (mAb) directed to the CD30 antigen expressed by tumor cells represent a key therapeutic tool, especially for treating relapsed/refractory (r/r) HL [16,17,18].